DK3233054T3 - Formuleringer af en PI3K/MTOR-hæmmer til intravenøs administration - Google Patents

Formuleringer af en PI3K/MTOR-hæmmer til intravenøs administration Download PDF

Info

Publication number
DK3233054T3
DK3233054T3 DK15813578.0T DK15813578T DK3233054T3 DK 3233054 T3 DK3233054 T3 DK 3233054T3 DK 15813578 T DK15813578 T DK 15813578T DK 3233054 T3 DK3233054 T3 DK 3233054T3
Authority
DK
Denmark
Prior art keywords
pi3k
formulations
intravenous administration
mtor inhibitor
mtor
Prior art date
Application number
DK15813578.0T
Other languages
Danish (da)
English (en)
Inventor
Kevin Richard Back
Michael Cram
Aidan James Harper
W James Huang
Jonathan Richard Lillis
Timothy Michael Lukas
Sumit Luthra
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK3233054T3 publication Critical patent/DK3233054T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK15813578.0T 2014-12-17 2015-12-10 Formuleringer af en PI3K/MTOR-hæmmer til intravenøs administration DK3233054T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093060P 2014-12-17 2014-12-17
US201562250633P 2015-11-04 2015-11-04
PCT/IB2015/059515 WO2016097949A1 (en) 2014-12-17 2015-12-10 Formulations of a pi3k/mtor-inhibitor for intravenous administration

Publications (1)

Publication Number Publication Date
DK3233054T3 true DK3233054T3 (da) 2021-08-02

Family

ID=54937330

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15813578.0T DK3233054T3 (da) 2014-12-17 2015-12-10 Formuleringer af en PI3K/MTOR-hæmmer til intravenøs administration

Country Status (25)

Country Link
US (2) US10172942B2 (cg-RX-API-DMAC7.html)
EP (1) EP3233054B1 (cg-RX-API-DMAC7.html)
JP (1) JP6420753B2 (cg-RX-API-DMAC7.html)
KR (1) KR102016822B1 (cg-RX-API-DMAC7.html)
CN (1) CN107205923B (cg-RX-API-DMAC7.html)
AU (1) AU2015365497B2 (cg-RX-API-DMAC7.html)
CA (1) CA2915199C (cg-RX-API-DMAC7.html)
CY (1) CY1124527T1 (cg-RX-API-DMAC7.html)
DK (1) DK3233054T3 (cg-RX-API-DMAC7.html)
ES (1) ES2881214T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211446T1 (cg-RX-API-DMAC7.html)
HU (1) HUE055928T2 (cg-RX-API-DMAC7.html)
IL (1) IL252158B (cg-RX-API-DMAC7.html)
LT (1) LT3233054T (cg-RX-API-DMAC7.html)
MX (1) MX380172B (cg-RX-API-DMAC7.html)
NZ (1) NZ731518A (cg-RX-API-DMAC7.html)
PL (1) PL3233054T3 (cg-RX-API-DMAC7.html)
PT (1) PT3233054T (cg-RX-API-DMAC7.html)
RS (1) RS62337B1 (cg-RX-API-DMAC7.html)
RU (1) RU2672875C1 (cg-RX-API-DMAC7.html)
SG (1) SG11201703826TA (cg-RX-API-DMAC7.html)
SI (1) SI3233054T1 (cg-RX-API-DMAC7.html)
TW (1) TWI660729B (cg-RX-API-DMAC7.html)
WO (1) WO2016097949A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201703764B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3672571T (lt) 2017-08-25 2021-12-10 Pfizer Inc. Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą
US12109308B2 (en) * 2018-06-07 2024-10-08 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yljcarbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
KR20240040768A (ko) 2021-07-26 2024-03-28 셀퀴티 인크. 암의 치료에 사용하기 위한 1-(4-{[4-(디메틸아미노)피페리딘-1-일]카르보닐}페닐)-3-[4-(4,6-디모르폴린-4-일-1,3,5-트리아진-2-일)페닐]우레아 (게다톨리십) 및 그의 조합물
WO2025128712A1 (en) 2023-12-12 2025-06-19 Celcuity Inc. Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea
US20260053814A1 (en) 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
AU2006251429A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising a diaryl urea compound and a PI3, AKT kinase or mTOR inhibitors (rapamycins) for cancer treatment
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
DE202008001253U1 (de) * 2008-01-28 2008-04-10 Mirror Image Ag Bildanzeigegerät
MY155653A (en) 2008-05-23 2015-11-13 Wyeth Llc Triazine compounds as p13 kinase and mtor inhibitors
ES2533788T3 (es) * 2008-05-30 2015-04-14 Genentech, Inc. Compuestos inhibidores de PI3K de tipo purina y métodos de uso
WO2010096619A1 (en) * 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
US9757432B2 (en) * 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
JP6309610B2 (ja) * 2013-03-14 2018-04-11 アブラクシス バイオサイエンス, エルエルシー 膀胱がんを処置する方法
EP3116547B1 (en) * 2014-03-14 2019-06-05 Pfizer Inc Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

Also Published As

Publication number Publication date
RU2672875C1 (ru) 2018-11-20
SG11201703826TA (en) 2017-07-28
JP6420753B2 (ja) 2018-11-07
RS62337B1 (sr) 2021-10-29
US20190105390A1 (en) 2019-04-11
MX380172B (es) 2025-03-12
SI3233054T1 (sl) 2021-11-30
HRP20211446T1 (hr) 2021-12-24
US20170360935A1 (en) 2017-12-21
JP2016113461A (ja) 2016-06-23
PT3233054T (pt) 2021-08-02
AU2015365497A1 (en) 2017-06-01
TW201632188A (zh) 2016-09-16
WO2016097949A1 (en) 2016-06-23
BR112017010841A2 (pt) 2017-12-26
AU2015365497B2 (en) 2020-07-02
PL3233054T3 (pl) 2021-12-20
HUE055928T2 (hu) 2022-01-28
KR102016822B1 (ko) 2019-08-30
EP3233054A1 (en) 2017-10-25
LT3233054T (lt) 2021-07-26
CA2915199C (en) 2018-11-06
CY1124527T1 (el) 2022-07-22
KR20170082638A (ko) 2017-07-14
US10172942B2 (en) 2019-01-08
CN107205923B (zh) 2021-03-05
US10660959B2 (en) 2020-05-26
EP3233054B1 (en) 2021-06-30
IL252158A0 (en) 2017-07-31
CN107205923A (zh) 2017-09-26
MX2017008072A (es) 2017-09-28
NZ731518A (en) 2019-03-29
CA2915199A1 (en) 2016-06-17
TWI660729B (zh) 2019-06-01
ZA201703764B (en) 2020-11-25
ES2881214T3 (es) 2021-11-29
IL252158B (en) 2021-01-31

Similar Documents

Publication Publication Date Title
DK3797742T3 (da) Indretning til suprakoroidal indgivelse af terapeutisk middel
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
DK3110475T3 (da) Indretning til administration af et fluidprodukt
DK3302638T3 (da) Anordning til indgivelse af lægemidler
DK3139986T3 (da) System til administration af terapeutisk gas
SI3769781T1 (sl) Stabilna formulacija proti-IFNAR1
DK3722274T3 (da) 2-perfluorbutylpentan til oftalmisk indgivelse
DK2968071T3 (da) Enhed til oral levering af terapeutiske forbindelser
DK3372585T3 (da) Fremgangsmåde til fremstillingen af en diarylthiohydantoinforbindelse
DK3831833T3 (da) Fremgangsmåder til fremstillingen af en pi3k-inhibitor
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3237045T3 (da) Indretning til indgivelse af lægemidler
DK3378482T3 (da) Formulering til administration af antitumorlægemiddel
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3116491T3 (da) Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
DK3204398T3 (da) Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3287133T3 (da) Proton-bindende polymerer til oral indgivelse
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
HUE049057T2 (hu) Proton-kötõ polimerek orális beadásra
DK2948134T3 (da) Sammensætninger til transdermal indgivelse af mtor-inhibitorer
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3149000T3 (da) Krystallinsk tosylatsalt af en pi3k-delta-selektiv inhibitor til anvendelse i farmaceutiske formuleringer
DK2981258T3 (da) Farmaceutiske formuleringer til subkutan indgivelse af furosemid
IL249674B (en) Quinolizinone derivatives as pi3k inhibitors